Aptevo Therapeutics, a biotech company, is at the forefront of developing five bispecific antibodies designed for both blood and solid tumors. Currently, two of these antibodies are undergoing clinical trials, while the remaining three are in the preclinical stages. This innovative approach holds great promise in the field of therapeutics, offering potential new treatment options […]
Category: Aptevo Therapeutics
Mipletamig Shows Promise in AML Treatment
In the rapidly evolving field of biotechnology, Aptevo Therapeutics is making waves with its cutting-edge work on Mipletamig. The clinical-stage biotech company has recently revealed promising clinical data from its ongoing Phase 1b/2 RAINIER trial. The trial evaluates Mipletamig, a first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza). This […]
